Placebo-Controlled Study of Mometasone Furoate Nasal Spray (MFNS) 200 mcg Once Daily (QD) in the Treatment of Seasonal Allergic Rhinitis (Study P05067)

Registry ID

EUCTR2014-004875-21

Source registry

EUCTR

Phase

PHASE3

Sponsor

Schering-Plough Research Institute, a Division of Schering Corporation

Last update

2026-08-16

Conditions

• Seasonal Allergic Rhinitis

Summary

The primary objective of this study was to assess the efficacy of mometasone furoate nasal spray (MFNS) once daily compared with placebo in subjects with seasonal allergic rhinitis (SAR) in reducing the total nasal symptom score (TNSS) and the total ocular symptom score (TOSS).

Related clinical trials

• Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study
• The Role of the Nasal Allergen Provocation Test in Starting and Monitoring Allergen Immunotherapy
• Clinical Study on TQH2722 Injection Combined With Background Therapy for Seasonal Allergic Rhinitis
• Study of CM310 in Patients With Uncontrolled Seasonal Allergic Rhinitis
• A Clinical Study on the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of SHR-1819 Injection in Patients With Seasonal Allergic Rhinitis
• Acupuncture at the Sphenopalatine Ganglion in the Treatment of Moderate-to-severe Seasonal Allergic Rhinitis

View on source registry